Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot, CSF
Aid in the diagnosis of paraneoplastic neurologic syndromes associated with malignancy for CSF specimens only.
Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot
Sun, Wed, Fri
New York DOH Approval Status
Transfer 2 mL CSF to an ARUP Standard Transport Tube. (Min: 0.75 mL)
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Ambient: 24 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
|Paraneoplastic Abs (PCCA/ANNA) IgG, CSF||None Detected|
|Neuronal Nuclear Ab Titer, IgG CSF||Less than 1:1|
|Purkinje Cell Antibody Titer IgG, CSF||Less than 1:1|
|2010847||Neuronal Nuclear Antibodies (Hu, Ri, Yo) IgG by Immunoblot, CSF||Effective August 17, 2020
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
PCCA/ANNA antibodies are screened by IFA. If the IFA screen is indeterminate then the Immunoblot will be added. If the IFA screen is positive at 1:1, then a specific titer (PCCA or ANNA) and Immunoblot will be added. Additional charges apply.
86255; if reflexed add 84182 x3 and/or 86256
|Component Test Code*||Component Chart Name||LOINC|
|2010842||Paraneoplastic Abs (PCCA/ANNA) IgG, CSF||14247-1|